Venezuelan Drug Industry Will Cooperate In Reform

9 June 1996

Venezuela's pharmaceutical industry association, the CAVEME, has said it is "prepared and disposed" to collaborate in the reform of the social security system as it concerns drug products, in the development of the sale of non-prescription drugs and medicines outside the pharmacy network and in the current discussion of legislation relating to drugs and intellectual property.

Raul Mejuto, re-elected as CAVEME president, said the position of the pharmaceutical industry over pending drug price deregulation by the government was to collaborate to ensure that the process is carried through in the "least traumatic" way possible.

Last month the government aproved a 60% increase in drug prices (Marketletter May 27) to compensate for the devaluation of Venezuela's currency, but at the same time stressed that prices will continue to be subjected to state control.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight